Raymond James Financial »

Summit Therapeutics shares owned by Raymond James Financial

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by Raymond James Financial from 13F filings

Historical chart of Raymond James Financial investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by Raymond James Financial consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by Raymond James Financial

Quarter filed Position value Share count Share price at filing
2025-09-30 $292k 14k 20.66
2025-06-30 $249k 12k 21.28

More positions owned by Raymond James Financial

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Microsoft Corporation (MSFT)
Ishares Tr Core Us Aggbd Et (AGG)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Broadcom (AVGO)
Amazon (AMZN)
JPMorgan Chase & Co. (JPM)
Ishares Tr Core Msci Eafe (IEFA)
Alphabet Cap Stk Cl A (GOOGL)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Meta Platforms Cl A (META)
Ishares Tr Core S&p500 Etf (IVV)
Wal-Mart Stores (WMT)
Ishares Tr Core S&p Mcp Etf (IJH)

View all positions for Raymond James Financial

Top funds holding Summit Therapeutics

Baker Bros. Advisors
Vanguard Group
FMR
BlackRock
State Street Corporation
Geode Capital Management
Susquehanna International
Pictet Asset Management Holding SA
Citadel Advisors
UBS Group
Apeiron Capital
Nomura Holdings
Standard Life Aberdeen
Squarepoint Ops
Sofinnova Ventures

View all funds holding Summit Therapeutics